PSORIASIS ADJUVANT THERAPY

Abstract

60 adult patients with moderate severity of psoriasis in progression phase of dermatosis were observed. In the combined therapy of methotrexate and topical glucocorticosteroid, the patients were additionally treated with Cetaphil® Restoraderm™ Skin restoring moisturizing lotion (hereinafter referred to as Cetaphil® RestoradermTM moisturizing lotion). In the course of treatment a multivariate evaluation of the functional and morphological parameters of the skin using the SOFT PLUS TOP apparatus (sebumetry, corneometry and elastometry), as well as assessment of severity, prevalence of psoriasis (PASI), quality of life of patients (DLQI) on the 14th and 28th days of observation was performed. It was found that the inclusion of moisturizing lotion in the combined therapy led to an earlier beginning of stabilization and regression of the psoriatic process, relief of subjective disorders, improvement of the quality of life of patients with psoriasis. Also statistically significant reduction of skin dryness and normalization of moistness and elasticity, which testifies to the expressed sebouregulating, elastogenic and moisturizing effects of this topical remedy, were observed.

Keywords

psoriasis / adjuvant therapy / efficacy / safety

References

[1] Feldman S.R. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013; 92(5): 258-63.

[2] Nast A., Boehncke W.H., Mrowietz U., Ockenfels H.M., Philipp S., Reich K., et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch. Dermatol. Ges. 2012; 10(Suppl. 2): S1-95.

[3] Menter А., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol. 2011; 65(1): 137-74.

[4] Федеральные клинические рекомендации по ведению больных псориазом. Российское общество дерматовенерологов и косметологов. М.; 2015. Available at: http://www.cnikvi.ru/docs/2335_maket_30.pdf

[5] Мордовцев В.Н. Псориаз. В кн.: Скрипкин Ю.К., ред. Кожные и венерические болезни. М.: Медицина; 1995. т.2: 179-230.

[6] Аравийская Е.Р., Cоколовский Е.В., ред. Руководство по дерматокосметологии. СПб.: Фолиант; 2008.

[7] Fluhr J.W., Cavallotti C., Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin. Dermatol. 2008; 26(4): 380-6.

[8] Schmuth M., Blunder S., Dubrac S., Gruber R., Moosbrugger-Martinz V. Epidermal barrier in hereditary ichthyoses, atopic dermatitis, and psoriasis. J. Dtsch. Dermatol. Ges. 2015; 13(11): 1119-23.

[9] Childhood psoriasis: often favorable outcome. Prescrire Int. 2009; 18(104): 275. Dawn A., Yosipovitch G. Treating itch in psoriasis. Dermatol. Nurs. 2006; 18(5): 227-33.

[10] Raut A.S., Prabhu R.H., Patravale V.B. Psoriasis clinical implications and treatment: a review. Crit. Rev. Ther. Drug. Carrier. Syst. 2013; 30(3): 183-216.

[11] Tidman M.J. Improving outcomes in patients with psoriasis. Practitioner. 2013; 257(1757): 27-30.

[12] Berne B., Blom I., Spångberg S. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single-blind controlled study. Acta Derm. Venereol. 1990; 70(6): 474-7.

[13] Boyvat A., Erdi H., Birol A., Gurgey E. Interaction of commonly used emollients with photochemotherapy. Photodermatol. Photoimmunol. Photomed. 2000; 16(4): 156-60.

[14] Finlay A. Emollients as adjuvant therapy for psoriasis. J. Dermatol. Treat. 1997; 8(Suppl. 1): S25-27. Available at: https://www.tandfonline.com/doi/abs/10.3109/09546639709160944

[15] Simpson E., Trookman N.S., Rizer R.L., Preston N., Colón L.E., Johnson L.A., et al. Safety and Tolerability of a Body Wash and Moisturizer when Applied to Infants and Toddlers with a History of Atopic Dermatitis: Results from an Open-Label Study. Pediatr. Dermatol. 2012, 29(5): 590-7.

[16] Del Rosso J.Q., Kircik L.H. The integration of physiologically-targeted skin care in the management of atopic dermatitis: focus on the use of a cleanser and moisturizer system incorporating a ceramide precursor, filaggrin degradation products, and specific “skin-barrier-friendly” excipients. J. Drugs Dermatol. 2013; 12(7): S85-91.

RIGHTS & PERMISSIONS

Eco-Vector